» Articles » PMID: 28652072

Evaluation of a Hepatitis C Education Intervention with Clients Enrolled in Methadone Maintenance and Needle/syringe Programs in Malaysia

Overview
Publisher Elsevier
Date 2017 Jun 28
PMID 28652072
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Approximately 40%-90% of people who inject drugs (PWID) in Malaysia have hepatitis C (HCV). PWID continue to be disproportionately affected by HCV due to their lack of knowledge, perceived risk and interest in HCV treatment. Education interventions may be an effective strategy for increasing HCV knowledge in PWID, and harm reduction services are uniquely positioned to implement and deploy such interventions.

Methods: We recruited 176 clients from methadone maintenance treatment (MMT: N=110) and needle/syringe programs (NSP: N=66) between November 2015 and August 2016. After baseline knowledge assessments, clients participated in a standardized, 45-min HCV education program and completed post-intervention knowledge assessments to measure change in knowledge and treatment interest.

Results: Participants were mostly male (96.3%), Malay (94.9%), and in their early 40s (mean=42.6years). Following the intervention, overall knowledge scores and treatment interest in MMT clients increased by 68% and 16%, respectively (p<0.001). In contrast, NSP clients showed no significant improvement in overall knowledge or treatment interest, and perceived greater treatment barriers. Multivariate linear regression to assess correlates of HCV knowledge post-intervention revealed that optimal dosage of MMT and having had an HIV test in the past year significantly increased HCV knowledge. Having received a hepatitis B vaccine, however, was not associated with increased HCV knowledge after participating in an education session.

Conclusion: Generally, HCV knowledge and screening is low among clients engaged in MMT and NSP services in Malaysia. Integrating a brief, but comprehensive HCV education session within harm reduction services may be a low-cost and effective strategy in improving overall HCV knowledge and risk behaviors in resource-limited settings. In order to be an effective public health approach, however, education interventions must be paired with strategies that improve social, economic and political outcomes for PWID. Doing so may reduce HCV disparities by increasing screening and treatment interest.

Citing Articles

Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study.

Kilonzo S, Gunda D, Majinge D, Jaka H, Manyiri P, Kalokola F BMC Infect Dis. 2021; 21(1):699.

PMID: 34289801 PMC: 8296674. DOI: 10.1186/s12879-021-06393-0.


Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.

Buggisch P, Heiken H, Mauss S, Weber B, Jung M, Gorne H PLoS One. 2021; 16(5):e0250833.

PMID: 33970940 PMC: 8109809. DOI: 10.1371/journal.pone.0250833.


Time to Treatment Initiation and Retrospective Analysis of Antiretroviral Therapy Outcomes among HIV-positive Methadone Maintenance Therapy Clients in Primary Health-care Centers, Kuantan, Pahang.

Ramlan A, Mohamed Nazar N, Tumian A, Ab Rahman N, Mohamad D, Abdul Talib M J Pharm Bioallied Sci. 2021; 12(Suppl 2):S810-S815.

PMID: 33828381 PMC: 8021067. DOI: 10.4103/jpbs.JPBS_3_20.


DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.

Zhang J, Li Z, Zhang L, Wang J, Huang L, Zhan G BMC Infect Dis. 2019; 19(1):774.

PMID: 31488064 PMC: 6727322. DOI: 10.1186/s12879-019-4421-5.


Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Patel E, Solomon S, McFall A, Srikrishnan A, Pradeep A, Nandagopal P Int J Drug Policy. 2018; 57:51-60.

PMID: 29679811 PMC: 5994190. DOI: 10.1016/j.drugpo.2018.03.023.

References
1.
Reid G, Kamarulzaman A, Sran S . Malaysia and harm reduction: the challenges and responses. Int J Drug Policy. 2007; 18(2):136-40. DOI: 10.1016/j.drugpo.2006.12.015. View

2.
Strain E, Bigelow G, Liebson I, Stitzer M . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11):1000-5. DOI: 10.1001/jama.281.11.1000. View

3.
Vicknasingam B, Narayanan S, Navaratnam V . Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Drug Alcohol Rev. 2009; 28(4):447-54. DOI: 10.1111/j.1465-3362.2009.00087.x. View

4.
Peles E, Schreiber S, Adelson M . Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2005; 82(3):211-7. DOI: 10.1016/j.drugalcdep.2005.09.004. View

5.
Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander L, Hickman M . Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(12):1385-1398. DOI: 10.1016/S1473-3099(16)30325-5. View